id: NEW:colistin_meropenem_combination_therapy_to_NEW:sofa_score
name: Colistin Plus Meropenem Combination Therapy â†’ Sequential Organ Failure Assessment
  Score
from_node:
  node_id: NEW:colistin_meropenem_combination_therapy
  node_name: Colistin Plus Meropenem Combination Therapy
to_node:
  node_id: NEW:sofa_score
  node_name: Sequential Organ Failure Assessment Score
direction: negative
category: biological
mechanism_pathway:
- 'Step 1: Colistin and meropenem act synergistically against multidrug-resistant
  gram-negative bacteria causing nosocomial pneumonia through complementary mechanisms
  - colistin disrupts bacterial outer membrane integrity while meropenem inhibits
  cell wall synthesis'
- 'Step 2: Enhanced bacterial clearance reduces the systemic inflammatory response
  and bacterial burden in the lungs and bloodstream'
- 'Step 3: Decreased infection severity leads to reduced organ dysfunction across
  multiple systems (respiratory, cardiovascular, hepatic, renal, coagulation, neurological)'
- 'Step 4: Improvement in organ function is reflected in lower Sequential Organ Failure
  Assessment (SOFA) scores, indicating better clinical outcomes'
evidence:
  quality_rating: B
  n_studies: 5
  primary_citation: Hazhir Moradi et al. 2024. Systematic review and meta-analysis
    of colistin plus meropenem therapy for the treatment of nosocomial pneumonia.
    Iranian journal of microbiology.
  supporting_citations: []
description: Colistin plus meropenem combination therapy significantly reduces Sequential
  Organ Failure Assessment (SOFA) scores compared to other colistin-based treatments
  in patients with nosocomial pneumonia caused by multidrug-resistant gram-negative
  bacteria. This meta-analysis of 5 studies with 991 patients demonstrated a statistically
  significant reduction in SOFA scores (OR = -0.28, 95% CI = -0.44 to -0.11, p = 0.001),
  indicating improved organ function with the combination therapy.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: -0.28
    type: standardized_mean_difference
    ci_lower: -0.44
    ci_upper: -0.11
  p_value: 0.001
  sample_size: 991
moderators:
- name: baseline_comorbidity_burden
  direction: weakens
  strength: moderate
  description: Higher Charlson Comorbidity Index scores were associated with the combination
    therapy group, suggesting patients with more comorbidities may still benefit but
    baseline severity may moderate treatment effects
- name: pathogen_susceptibility
  direction: strengthens
  strength: moderate
  description: Effectiveness likely depends on susceptibility patterns of causative
    gram-negative organisms to the combination therapy
